Skip to main content
. 2017 Dec 21;9(2):2810–2818. doi: 10.18632/oncotarget.23596

Figure 2.

Figure 2

Log-rank tests of CSS comparing patients with NLNs (≤6 VS >6) for (A) FIGO stage I: χ2 = 35.023, P < 0.001; (B) FIGO stage II: χ2 = 12.910, P < 0.001; and (C) FIGO stage III + IV: χ2 = 9.732, P = 0.002 and (D) Unknown stage: χ2 = 16.654, P < 0.001.